Hot AI Mandate: Taiwan-based Drug Delivery System Manufacturer Seeks Joint Ventures, Strategic Partnership and Other Opportunities Globally in All Areas of Medtech and Healthcare IT

2 May

A corporate venture firm founded in 2020 is headquartered in Denver, Colorado. The firm’s typical check size ranges from $1-10M in Seed stage and beyond, with Series A being their sweet spot. Because of the flexibility in their balance sheet and investment committee, the firm has also looked at investments greater than $10M in Series C and D companies. The firm typically makes equity investments but has used notes for later stage investments. The firm is USA focused but will look at companies headquartered elsewhere if there’s USA commercial traction or intent to commercialize in the US.

The firm is interested in diagnostic and digital health sectors and is open to all subsectors and indications. The firm is not interested in therapeutics or medical devices, unless they’re noninvasive medical devices. The firm is especially interested in technology that impacts their polychronic patients, especially since the firm has a strong intention of moving upstream into the CKD and ESKD space. The firm has done a lot of work in the cardiometabolic and comorbidity space, more specifically looking at technology for cardiovascular disease, diabetes, COPD, social determinants of health, end of life and behavioral health.

The firm prefers management teams with entrepreneurial experience but is open to all types of management teams and has backed first-time founders. For companies not in the diagnostics or device space, The firm likes to see at least $1M in ARR. The firm has led in the past but prefers to join syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The Power of Capital Investors and Licensing Partners Data

28 Apr

By Rory McCann, Marketing Manager & Conference Producer, LSN

Launching a successful startup requires data. Life science entrepreneurs know the value of data when pitching to investors, but those investor meetings don’t happen without a well-curated dataset and global target list (GTL). In a recent conversation with Life Science Nation (LSN) business development manager Alex Vassallo, we discussed how fundraising founders can source a GTL of investors and strategic partners who are a fit for their product and stage of development using the LSN Investor Database, and how to use this tool in conjunction with tried-and-true principles of successful partnering.

Contact us to learn more about the LSN Investor Database, view a demo, and discuss how our products and services can help your early-stage fundraise.

Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International
East Coast (USA) & China
Midwest (USA)
& Canada
West Coast  (USA)
Alex
Greg Mannix
Vice President International Business Development
Book a Meeting
Email Me
Candice He
VP, Business Development & Global Investment Strategist
Book a Meeting
Email Me
Antoinette Lowre
Manager of Business Development
Book a Meeting
Email Me
Alexander Vassallo
Manager of Business Development
Book a Meeting
Email Me

Last Chance to Pitch!

28 Apr

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claireThere are still pitching slots available for Digital RESI, June 7-9! The deadline for the Innovator’s Pitch Challenge (IPC) is tomorrow, April 29. The IPC is a great opportunity to showcase your company and stand out among RESI’s community of investors and strategic partners. A recent IPC winner spoke with our team to share their process as a first-time RESI attendee and pitching company. Check out Bold Therapeutics’ interview here.

The IPC includes unique benefits to maximize your pitching experience:

  • Dedicated Webpage: Each IPC finalist company will have their own dedicated landing page, which will include a short pitch video, slide deck, executive summary, and other marketing collateral they wish to highlight that is relevant to their company.
  • Enhanced Visibility: The RESI live agenda will open a few days prior to the conference for judges and attendees to review finalist company materials. The agenda will remain live for a month following the event.
  • Live Q&A: IPC finalists are grouped with other companies based on sector and technology and will be assigned to a one-hour Q&A session with a panel of investors and industry experts who actively invest in and work with similar technology. All judges are instructed to review pitch videos before the session, enabling them to ask more targeted, high-level questions. After the session is over, IPC finalists are connected with participating investors via email.

The IPC has grown into one of RESI’s most popular and valuable features. The deadline to apply is tomorrow, Friday, April 29.

*A one-day or three-day registration + $800 pitch fee are required to participate.

Fulbright Scholars Learn to Fly with Life Science Nation

28 Apr

By Alexander Vassallo, Manager of Business Development West Coast (US), LSN

“If I told you to jump out of an airplane without a parachute, would you do it?”

This was not the first question that the Fulbright scholars attending the Boston seminar were expecting to receive, but after a 3-day entrepreneurial masterclass workshop delivered by Life Science Nation (LSN), it was a question all the scholars had an answer to. Starting a company is one of the most difficult tasks an entrepreneur can undertake, however, with the right mindset and genuine entrepreneurial agency, your chances of success can greatly improve.

The Fulbright Commission invited LSN to help equip the next generation of aspiring scientist-entrepreneurs with some of the skills they would need to be industry leaders in the life science arena. Led by LSN Founder and CEO, Dennis Ford, alongside the VP of Business Development, Candice He, and the BD Manager for the West Coast, Alex Vassallo, the Boston Fulbright seminar, April 21-23, was an engaging experience that this year’s cohort of scholars would not soon forget.

Participants were given an opportunity to explore and examine the process of taking life-saving inventions from ideation and creation stages to the public market. The life science domain is unique in that a startup entity’s journey starts with academic tech transfer agreements, which lead to regional and national government non-dilutive funding followed by capital investors and licensing partners. This entrepreneurial masterclass highlighted the core elements of launching an early-stage company’s branding and messaging in conjunction with a global partnering campaign. The theme of the workshop was finding your entrepreneurial voice, developing a compelling narrative, and then clearly telling the story of team, product, company milestones, and partnering strategy.

The 3-day entrepreneurial workshop concluded with an impressive pitch competition that highlighted not only the talent and entrepreneurial agency that the Fulbright scholars possessed, but that the key take-home messages of the masterclass had been well integrated and understood. We can expect many of these students to be industry leaders in the coming years and were honored to be a part of their journey. Whilst starting a company in many ways is comparable to jumping out of an airplane without a parachute, the scholars of the Fulbright Commission are taking the plunge.

Hot Investor Mandate: USA VC Firm Seeks Technologies in the Convergence of Life Sciences and AI, Investing Up to $10M in Devices, Digital Health, Advanced Materials, and More

28 Apr

A venture capital firm with multiple offices in the USA partners with and invests in entrepreneurs who are developing breakthrough products leveraging the convergence of biology and/or hardware with advanced computation and AI (referred to as Convergent Tech). The firm employs a multi-stage investment strategy, encompassing both seed and venture investment programs, and assist entrepreneurs with recruiting and customer and supply chain business development. The firm is generally a lead investor, and invests up to $10 million per opportunity; the firm also has an active seed fund that invests smaller amounts at earlier development stages.

The firm invests in life science start-ups developing advanced materials, process, and device technologies that leverage advanced computational approaches such as deep learning, and unique data generation capabilities. Specific areas of interest include drug discovery platforms, manufacturing platforms, drug delivery platforms, non-invasive diagnostics, and sustainability generally. The firm does not invest in pure-play therapeutic clinical development business models.

The firm favors companies with platform technologies and partnership-based business models. The firm has deep expertise in manufacturing and productization. Additionally, LPs include large pharma and medical device manufacturing companies; Phoenix Venture Partners helps portfolio companies develop relationships with these strategics.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC with USA and Asia Offices Actively Invests in Early-Stage Medical Device, Digital Health, and Synthetic Biology Companies With Asia Market Expansion Potential

28 Apr

A venture capital firm based in USA and Singapore makes early up to expansion stage investments across several industries including healthcare. The investment size is highly variable depending on the stage of the company. The firm invests in companies in North America and Europe that has a market expansion strategy in Asia and/or Singapore. The firm is actively seeking new investment opportunities.

In the Life Sciences, the firm is currently seeking medical devices, synthetic biology and HCIT. For medical devices, the firm is opportunistic in terms of subsectors and indications. The firm looks for devices that are ready for commercialization. The firm is currently not looking for drug development companies.The firm seeks entrepreneurs who are passionate, driven and enthusiastic, with sustainable business models and ideas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Firm Seeks to Invest in Digital Health Companies Including Healthcare Services, Mainly in Seed to Series A Rounds in USA Headquartered Companies

28 Apr

A venture capital firm based in the USA is interested in a broad range of technology companies, including those in the software, cloud services, IT, and Internet sectors. In the life sciences, the firm will only invest in the healthcare IT sector. The firm invests in late seed to early Series A rounds with a typical investment size ranges from $1M-$5M. Investment is typically in form of equity, though convertible notes would be considered as well. The firm will look at investment opportunities across the US West Coast and in Texas.

The firm will make new investments in the digital health sector. The firm is interested in healthcare services and IT companies targeting platform, enterprise software, m-health, solution, data analytics and consumer health. The firm will invest in commercial-stage companies with products or services on the market.

The firm invests in privately held healthcare companies. The firm focuses on companies with annual revenues of between $0.5M and $10M.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →